Abstract：
OBJECTIVE: The relationship between anti-SSA/RO antibodies and pregnancy has been reported previously, and we aim to visualize the rates of maternal and infant outcomes with anti-SSA/RO.
METHODS: We systematically searched records from Pubmed, Cochrane, Embase, and Web of Science databases, pooled incidence rates of adverse outcomes of pregnancy, and 95% confidence intervals (CIs) were performed with RStudio.
RESULTS: A total of 890 records comprising 1675 patients and 1920 pregnancies were searched from the electronic databases. For maternal outcomes, the pooled estimate rates were 4% for termination of pregnancy, 5% for spontaneous abortion, 26% for preterm labor, and 50% for cesarean operation. While for fetal outcomes, the pooled estimate rates were 4% for perinatal death, 3% for intrauterine growth retardation, 6% for endocardial fibroelastosis, 6% for dilated cardiomyopathy, 7% for congenital heart block, 12% for congenital heart block recurrence, 19% for cutaneous neonatal lupus erythematosus, 12% for hepatobiliary disease and 16% for hematological manifestations. A subgroup analysis of congenital heart block prevalence was performed, diagnostic method and study region were found to affect heterogeneity to some extent.
CONCLUSIONS: Cumulative analysis of data from real-world studies confirmed adverse pregnancy outcomes of women with anti-SSA/RO, serves as a reference and a guide for the diagnosis and subsequent treatment of these women, thereby enhancing maternal and infant health. Additional studies with real-world cohorts are required to validate these results.
METHODS: We systematically searched records from Pubmed, Cochrane, Embase, and Web of Science databases, pooled incidence rates of adverse outcomes of pregnancy, and 95% confidence intervals (CIs) were performed with RStudio.
RESULTS: A total of 890 records comprising 1675 patients and 1920 pregnancies were searched from the electronic databases. For maternal outcomes, the pooled estimate rates were 4% for termination of pregnancy, 5% for spontaneous abortion, 26% for preterm labor, and 50% for cesarean operation. While for fetal outcomes, the pooled estimate rates were 4% for perinatal death, 3% for intrauterine growth retardation, 6% for endocardial fibroelastosis, 6% for dilated cardiomyopathy, 7% for congenital heart block, 12% for congenital heart block recurrence, 19% for cutaneous neonatal lupus erythematosus, 12% for hepatobiliary disease and 16% for hematological manifestations. A subgroup analysis of congenital heart block prevalence was performed, diagnostic method and study region were found to affect heterogeneity to some extent.
CONCLUSIONS: Cumulative analysis of data from real-world studies confirmed adverse pregnancy outcomes of women with anti-SSA/RO, serves as a reference and a guide for the diagnosis and subsequent treatment of these women, thereby enhancing maternal and infant health. Additional studies with real-world cohorts are required to validate these results.
摘要：
目的：抗SSA/RO抗体与妊娠的关系已有报道，我们的目标是可视化抗SSA/RO的母婴结局率。
方法：我们系统地从Pubmed，科克伦,Embase,和WebofScience数据库,妊娠不良结局的汇总发生率，用RStudio进行95%置信区间(CI)。
结果：从电子数据库中检索了890条记录，包括1675例患者和1920例妊娠。对于产妇结局，终止妊娠的汇总估计率为4%，5％为自然流产，26％的早产，50%为剖宫产手术。而对于胎儿结局，围产期死亡的汇总估计率为4%，3%为宫内发育迟缓，6%用于心内膜弹性纤维增生症，6%为扩张型心肌病，7%为先天性心脏传导阻滞，12%为先天性心脏传导阻滞复发，19%为新生儿皮肤红斑狼疮，肝胆疾病为12％，血液学表现为16％。进行了先天性心脏传导阻滞患病率的亚组分析，诊断方法和研究区域在一定程度上影响异质性。
结论：对来自真实世界研究的数据的累积分析证实，抗SSA/RO妇女的不良妊娠结局，作为这些妇女的诊断和后续治疗的参考和指南，从而增强母婴健康。需要对真实世界队列进行其他研究来验证这些结果。
方法：我们系统地从Pubmed，科克伦,Embase,和WebofScience数据库,妊娠不良结局的汇总发生率，用RStudio进行95%置信区间(CI)。
结果：从电子数据库中检索了890条记录，包括1675例患者和1920例妊娠。对于产妇结局，终止妊娠的汇总估计率为4%，5％为自然流产，26％的早产，50%为剖宫产手术。而对于胎儿结局，围产期死亡的汇总估计率为4%，3%为宫内发育迟缓，6%用于心内膜弹性纤维增生症，6%为扩张型心肌病，7%为先天性心脏传导阻滞，12%为先天性心脏传导阻滞复发，19%为新生儿皮肤红斑狼疮，肝胆疾病为12％，血液学表现为16％。进行了先天性心脏传导阻滞患病率的亚组分析，诊断方法和研究区域在一定程度上影响异质性。
结论：对来自真实世界研究的数据的累积分析证实，抗SSA/RO妇女的不良妊娠结局，作为这些妇女的诊断和后续治疗的参考和指南，从而增强母婴健康。需要对真实世界队列进行其他研究来验证这些结果。
